Sign In
Buy SAVA
$1.96
+0 (+0%)
At Close: Jun 03, 2026
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
08:28am, Friday, 27'th Sep 2024
Alzheimer's drug developer Cassava Sciences Inc SAVA, its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC charges over misle
Cassava Sciences settles SEC charges of ‘misleading' Alzheimer's trial claims
06:29pm, Thursday, 26'th Sep 2024
Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former
Cassava Sciences Resolves SEC Investigation
06:15pm, Thursday, 26'th Sep 2024
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announced th
SEC Charges Cassava Sciences, Two Former Executives for Misleading Claims About Alzheimer's Clinical Trial
06:14pm, Thursday, 26'th Sep 2024
Washington, D.C.--(Newsfile Corp. - September 26, 2024) - The Securities and Exchange Commission today announced Cassava Sciences, Inc., its founder and former CEO, Remi Barbier, and its former Senior
US charges Cassava Sciences, two former executives for misleading claims about Alzheimer's clinical trial
05:46pm, Thursday, 26'th Sep 2024
The U.S. Securities and Exchange Commission said on Thursday that it charged Cassava Sciences and two of the company's former executives for misleading claims about the results of Alzheimer's clinical
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
08:30am, Tuesday, 24'th Sep 2024
AUSTIN, Texas, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announced the completion of a third interim safet
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
08:31am, Tuesday, 03'rd Sep 2024
AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it has been invited
Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
07:00am, Saturday, 10'th Aug 2024
Cassava Sciences NASDAQ: SAVA has become a hot topic among traders and active market participants thanks to its recent surge in volatility, liquidity, and overall market performance. Over the past mon
Cassava Sciences Q2 Earnings Review: So Many Questions, So Few Answers
01:53pm, Thursday, 08'th Aug 2024
Cassava Sciences, Inc. announced its Q2 earnings earlier today. Management says it hopes to share pivotal Phase 3 study data for Alzheimer's drug candidate simufilam in 2024. The CEO and Head of Resea
2 Biotech Stocks Making Moves Today
03:06pm, Tuesday, 06'th Aug 2024
Last month, we took a look at three biotech stocks following a historically bullish month for biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI).
Cassava Sciences News: Why Is SAVA Stock Trending Today?
10:00am, Tuesday, 06'th Aug 2024
Cassava Sciences (NASDAQ: SAVA ) stock is a hot topic among traders on Tuesday alongside a few important pieces of news that investors need to know about this morning. First off, traders will note tha
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
09:01am, Monday, 05'th Aug 2024
AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today reflected on the passing of long-time board member Sanford Robertson.
Get Your Money Out of These 3 Healthcare Stocks ASAP
06:55am, Friday, 02'nd Aug 2024
In general, I'm quite bullish on the healthcare sector. Many of the names in the space have extremely low valuations because a high percentage of investors irrationally believed that healthcare compan
AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a confe
SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months
12:32pm, Tuesday, 30'th Jul 2024
A struggling biotech stock is on the move today on news of a trial extension. Indeed, Cassava Sciences (NASDAQ: SAVA ) has announced that it will be extending trials of simufilam — its lead Alzheime
